INCYIncyte CorporationSigning up patients
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Solid Tumors
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 588 (planned)
- Started
- Apr 9, 2026
- Main results expected
- Sep 15, 2028
- Fully finished
- Mar 19, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: Up to approximately 3 years
Progression-free survival (PFS) by BICR
Measured over: Up to approximately 2 years
Objective Response by BICR
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07522073 · record last updated 2026-10-30 · checked 2026-11-09 15:42 UTC